Haemonetics Corporation (NYSE: HAE) closed at $121.29, up $0.18 or 0.15%, as the medical technology company traded near the upper end of its recent range. With a market capitalization of approximately $5.52 billion and its next earnings report scheduled for November 5, investors are watching the company’s performance across plasma collection, blood management, and hospital technologies.
Stock Performance and Market Data
Haemonetics finished the session on October 15 at $121.29, slightly above its previous close of $121.11. The stock opened at $122.20 and traded between $118.65 and $122.46 during the session. Its five-day chart showed a modest gain of approximately 1.52%, despite a pullback during the latest trading period.
The stock’s 52-week range stands at $48.62 to $123.77, placing the latest closing price near its yearly high. Trading volume reached 740,761 shares, close to the average volume of 735,158. Haemonetics reported trailing earnings per share of $2.06 and a trailing price-to-earnings ratio of 58.88. The displayed one-year analyst target estimate was $124.50.
Business Overview
Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics develops medical technology and software used in hospitals and blood-related healthcare services. Its operations span Plasma, Blood Center, and Hospital segments, with products designed to support plasma collection, donor management, transfusion management, and surgical care.
Its portfolio includes NexSys PCS plasmapheresis equipment, NexLynk DMS donor management software, and Donor360 tools. In hospitals, the company offers technologies for electrophysiology, critical care, trauma, burn surgery, spine surgery, and cancer surgery. Its products also include the TEG 6s hemostasis analyzer, TEG Manager software, and VASCADE vascular closure systems.
Upcoming Earnings and Market Outlook
Haemonetics is scheduled to report earnings on November 5, 2026. The upcoming report may provide investors with updated information about the company’s operating performance and demand across its medical technology businesses.
The stock’s proximity to its 52-week high indicates that it has recovered substantially from its yearly low. However, the displayed valuation metrics, including a trailing P/E ratio of 58.88, make future earnings performance an important consideration for investors assessing the share price.
Risks and Challenges
Haemonetics operates in specialized medical technology markets where product performance, hospital purchasing decisions, competition, and regulatory requirements can influence results. Investors should also consider whether earnings growth can support the company’s valuation. The provided market data does not establish a specific catalyst behind the latest share-price movement.
Closing Paragraph
Haemonetics ended the session slightly higher at $121.29, with trading volume near its recent average and the share price approaching its 52-week high. With earnings scheduled for November 5, the next report will be an important point of reference for evaluating the company’s financial performance and outlook.
